{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:25:30Z","timestamp":1780572330156,"version":"3.54.1"},"reference-count":92,"publisher":"International Society of Global Health","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Glob Health"],"DOI":"10.7189\/jogh.12.04026","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T13:27:58Z","timestamp":1647955678000},"source":"Crossref","is-referenced-by-count":22,"title":["A systematic review of clinical practice guidelines for myopic macular degeneration"],"prefix":"10.7189","volume":"12","author":[{"given":"Yanxian","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China"},{"name":"State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Han","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Gordon","sequence":"additional","affiliation":[{"name":"Cochrane Eyes and Vision, International Centre for Eye Health, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sare","family":"Safi","sequence":"additional","affiliation":[{"name":"Ophthalmic Epidemiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Lingham","sequence":"additional","affiliation":[{"name":"Centre for Ophthalmology and Visual Science, Lions Eye Institute, University of Western Australia, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Evans","sequence":"additional","affiliation":[{"name":"Cochrane Eyes and Vision, International Centre for Eye Health, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingguang","family":"He","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China"},{"name":"State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China"},{"name":"Centre for Eye Research Australia; Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Keel","sequence":"additional","affiliation":[{"name":"Vision and Blindness Prevention Programme, World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4223","published-online":{"date-parts":[[2022,3,26]]},"reference":[{"key":"key-10.7189\/jogh.12.04026-202203221410-R1","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.ophtha.2006.04.022","article-title":"Prevalence and Causes of Low Vision and Blindness in a Japanese Adult Population: The Tajimi Study.","volume":"113","author":"Iwase","year":"2006","journal-title":"Ophthalmology"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R2","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study.","volume":"9","author":"GBD 2019 Blindness and Vision Impairment Collaborators, Vision Loss Expert Group of the Global Burden of Disease Study","year":"2021","journal-title":"Lancet Glob Health"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R3","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/j.ophtha.2010.01.020","article-title":"Prevalence and Progression of Myopic Retinopathy in Chinese Adults: The Beijing Eye Study.","volume":"117","author":"Liu","year":"2010","journal-title":"Ophthalmology"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R4","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1001\/archophthalmol.2011.230","article-title":"Prevalence and characteristics of myopic retinopathy in a rural chinese adult population: The handan eye study.","volume":"129","author":"Gao","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R5","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/j.ophtha.2012.02.034","article-title":"Prevalence and risk factors for myopic retinopathy in a Japanese population: the Hisayama Study.","volume":"119","author":"Asakuma","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R6","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S0161-6420(01)01024-7","article-title":"Prevalence and progression of myopic retinopathy in an older population.","volume":"109","author":"Vongphanit","year":"2002","journal-title":"Ophthalmology"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R7","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1167\/iovs.18-24032","article-title":"Prevalence, Risk Factors, and Impact of Myopic Macular Degeneration on Visual Impairment and Functioning Among Adults in Singapore.","volume":"59","author":"Wong","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R8","doi-asserted-by":"publisher","first-page":"5579","DOI":"10.1167\/iovs.12-10106","article-title":"Prevalence of myopia and its association with body stature and educational level in 19-year-old male conscripts in seoul, South Korea.","volume":"53","author":"Jung","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R9","doi-asserted-by":"publisher","first-page":"7504","DOI":"10.1167\/iovs.11-8343","article-title":"High prevalence of myopia and high myopia in 5060 Chinese university students in Shanghai.","volume":"53","author":"Sun","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3109\/09286586.2014.928824","article-title":"Differences in prevalence of refractive errors in young Asian males in Singapore between 1996\u20131997 and 2009\u20132010.","volume":"21","author":"Koh","year":"2014","journal-title":"Ophthalmic Epidemiol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.47102\/https:\/\/doi.org\/10.47102\/annals-acadmedsg.V33N1p27","article-title":"Prevalence of myopia in Taiwanese schoolchildren: 1983 to 2000.","volume":"33","author":"Lin","year":"2004","journal-title":"Ann Acad Med Singap"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R12","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/bjo.85.9.1041","article-title":"Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients.","volume":"85","author":"Ruiz-Moreno","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R13","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/S0002-9394(02)01335-1","article-title":"Surgical treatment of subfoveal neovascularization in myopia: macular translocation vs surgical removal.","volume":"133","author":"Hamelin","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R14","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1097\/IAE.0b013e31820668cf","article-title":"Treatment of non-age-related macular degeneration submacular diseases with macular translocation surgery.","volume":"31","author":"Ehlers","year":"2011","journal-title":"Retina"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/BF00930311","article-title":"Laser photocoagulation of choroidal neovascularization in pathologic myopia: long-term results.","volume":"18","author":"Pece","year":"1994-1995","journal-title":"Int Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/112067210201200207","article-title":"Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes.","volume":"12","author":"Ruiz-Moreno","year":"2002","journal-title":"Eur J Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R17","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1097\/01.iae.0000244256.60524.c0","article-title":"Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia: long-term study.","volume":"26","author":"Pece","year":"2006","journal-title":"Retina"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1136\/bjo.87.2.173","article-title":"Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation.","volume":"87","author":"Montero","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S0161-6420(01)00544-9","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin.","volume":"108","author":"Verteporfin in Photodynamic Therapy Study Group","year":"2001","journal-title":"Ophthalmology"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ajo.2004.10.005","article-title":"The safety profile of long-term, high-dose intraocular corticosteroid delivery.","volume":"139","author":"Holekamp","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R21","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1136\/bjo.2006.103606","article-title":"Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.","volume":"91","author":"Chan","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R22","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R23","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/eye.2013.8","article-title":"Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study.","volume":"27","author":"Tufail","year":"2013","journal-title":"Eye (Lond)"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R24","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","article-title":"RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.","volume":"121","author":"Wolf","year":"2014","journal-title":"Ophthalmology"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R25","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1136\/bjophthalmol-2012-302973","article-title":"Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome.","volume":"97","author":"Ruiz-Moreno","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R26","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","article-title":"Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study.","volume":"122","author":"Ikuno","year":"2015","journal-title":"Ophthalmology"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R27","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.preteyeres.2017.10.005","article-title":"Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia.","volume":"63","author":"Ohno-Matsui","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R28","doi-asserted-by":"publisher","first-page":"e000533","DOI":"10.1136\/bmjophth-2020-000533","article-title":"Strengthening the integration of eye care into the health system: methodology for the development of the WHO package of eye care interventions.","volume":"5","author":"Keel","year":"2020","journal-title":"BMJ Open Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R29","doi-asserted-by":"crossref","unstructured":"Wallace BC, Small K, Brodley CE, Lau J, Trikalinos TA. Deploying an interactive machine learning system in an evidence-based practice center: abstrackr. Proceedings of the 2nd ACM SIGHIT International Health Informatics Symposium. Miami, Florida, USA: Association for Computing Machinery; 2012.","DOI":"10.1145\/2110363.2110464"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12913-018-2954-8","article-title":"Guideline appraisal with AGREE II: online survey of the potential influence of AGREE II items on overall assessment of guideline quality and recommendation for use.","volume":"18","author":"Hoffmann-E\u00dfer","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R31","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1016\/j.apmr.2019.06.002","article-title":"Toward strengthening rehabilitation in health systems: methods used to develop a WHO package of rehabilitation interventions.","volume":"100","author":"Rauch","year":"2019","journal-title":"Arch Phys Med Rehabil"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R32","unstructured":"The Royal College of Ophthalmologists. Primary Eye Care Community Ophthalmology and General Ophthalmology. 2019."},{"key":"key-10.7189\/jogh.12.04026-202203221410-R33","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/cxo.12544","article-title":"Infection control guidelines for optometrists 2016.","volume":"100","author":"Lian","year":"2017","journal-title":"Clin Exp Optom"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R34","unstructured":"National Institute for Health and Care Excellence. Ranibizumab; The clinician's guide to commencing, continuing, and discontinuing treatment. 2009."},{"key":"key-10.7189\/jogh.12.04026-202203221410-R35","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000486145","article-title":"2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations.","volume":"239","author":"Grzybowski","year":"2018","journal-title":"Ophthalmologica"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R36","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1542\/peds.2011-0020","article-title":"US Preventive Services Task Force vision screening recommendations.","volume":"127","author":"Donahue","year":"2011","journal-title":"Pediatrics"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R37","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1097\/IAE.0000000000000627","article-title":"Treat-and-extend regimens with anti-vegf agents in retinal diseases: A Literature Review and Consensus Recommendations.","volume":"35","author":"Freund","year":"2015","journal-title":"Retina"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R38","unstructured":"The American Optometric Association. Comprehensive adult eye and vision examination. 2015."},{"key":"key-10.7189\/jogh.12.04026-202203221410-R39","unstructured":"American Academy of Ophthalmology. Comprehensive Adult Medical Eye Evaluation PPP. 2015."},{"key":"key-10.7189\/jogh.12.04026-202203221410-R40","unstructured":"National Institute for Health and Care Excellence. NICE Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occulsion. 2014."},{"key":"key-10.7189\/jogh.12.04026-202203221410-R41","unstructured":"National Institute for Health and Care Excellence. Ranibizumab for treating VI caused by macular oedema. 2013."},{"key":"key-10.7189\/jogh.12.04026-202203221410-R42","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1001\/jama.2016.0763","article-title":"Screening for Impaired Visual Acuity in Older Adults: US Preventive Services Task Force Recommendation Statement.","volume":"315","author":"Siu","year":"2016","journal-title":"JAMA"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R43","unstructured":"Royal College of Anaesthetists and Royal College of Ophthalmologists. Local Anaesthesia in Ophthalmic Surgery 2012. 2012."},{"key":"key-10.7189\/jogh.12.04026-202203221410-R44","unstructured":"The Royal Australian and New Zealand College of Ophthalmologists. Guidelines for Performing Intravitreal Therapy. 2017."},{"key":"key-10.7189\/jogh.12.04026-202203221410-R45","unstructured":"The Royal College of Ophthalmologists. Intravitreal Injection Therapy. 2018."},{"key":"key-10.7189\/jogh.12.04026-202203221410-R46","unstructured":"The Royal College of Ophthalmologists. Ophthalmic Imaging. 2019."},{"key":"key-10.7189\/jogh.12.04026-202203221410-R47","doi-asserted-by":"publisher","first-page":"E588","DOI":"10.1503\/cmaj.171430","article-title":"Screening for impaired vision in community-dwelling adults aged 65 years and older in primary care settings.","volume":"190","author":"Wilson","year":"2018","journal-title":"CMAJ"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R48","unstructured":"The Royal College of Ophthalmologists. Theatre facilities and equipment. 2018."},{"key":"key-10.7189\/jogh.12.04026-202203221410-R49","unstructured":"The Royal College of Ophthalmologists. Theatre Procedures. 2018."},{"key":"key-10.7189\/jogh.12.04026-202203221410-R50","unstructured":"The Welsh Government for the NHS Wales. Eye Health Examinations Wales (EHEW); manual and protocols (WHC 2014 007 14). 2014."},{"key":"key-10.7189\/jogh.12.04026-202203221410-R51","unstructured":"The Royal College of Ophthalmologists. Prevention of transmission of blood-borne viruses in ophthalmic surgery. 2010."},{"key":"key-10.7189\/jogh.12.04026-202203221410-R52","unstructured":"National Institute for Health and Care Excellence. Eye conditions. 2019."},{"key":"key-10.7189\/jogh.12.04026-202203221410-R53","first-page":"17","article-title":"Management of common eye conditions in a primary health care setting; a guide for South Sudan health workers.","volume":"10","author":"Gindala","year":"2017","journal-title":"South Sudan Med J"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R54","unstructured":"The Royal College of Ophthalmologists. Managing an outbreak of postoperative endophthalmitis. 2016."},{"key":"key-10.7189\/jogh.12.04026-202203221410-R55","unstructured":"The Clinical Council for Eye Health Commissioning (CCEHC). Strategy 2016 - 2018 - Commissioning for the needs of the patients ; enhancing eye health services."},{"key":"key-10.7189\/jogh.12.04026-202203221410-R56","unstructured":"The Royal Australian and New Zealand College of Ophthalmologists. Fluorescein and Indocyanine Green Angiography Guidelines. 2015."},{"key":"key-10.7189\/jogh.12.04026-202203221410-R57","unstructured":"The Royal Australian and New Zealand College of Ophthalmologists. Infection Control in Surgery \u2013 Hepatitis B Hepatitis C and HIV (1). 2019."},{"key":"key-10.7189\/jogh.12.04026-202203221410-R58","unstructured":"The Royal Australian and New Zealand College of Ophthalmologists. RANZCO Laser Safety Protocol. 2015."},{"key":"key-10.7189\/jogh.12.04026-202203221410-R59","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","article-title":"Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases.","volume":"255","author":"Lanzetta","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R60","unstructured":"The Royal Australian and New Zealand College of Ophthalmologists. Ocular Surgery Guidelines for Ensuring Correct Patient, Correct Eye, Correct Site and Correct Procedure. 2019."},{"key":"key-10.7189\/jogh.12.04026-202203221410-R61","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.ophtha.2017.04.028","article-title":"Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management.","volume":"124","author":"Cheung","year":"2017","journal-title":"Ophthalmology"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R62","first-page":"232","article-title":"Optimising the management of choroidal neovascularisation in Asian patients: consensus on treatment recommendations for anti-VEGF therapy.","volume":"52","author":"Koh","year":"2011","journal-title":"Singapore Med J"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R63","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4103\/jovr.jovr_50_18","article-title":"Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents for Ocular Vascular Diseases: Clinical Practice Guideline.","volume":"13","author":"Nikkhah","year":"2018","journal-title":"J Ophthalmic Vis Res"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R64","unstructured":"National Institute for Health and Care Excellence. Ranibizumab for treating choroidal neovascularisation associated with pathological myopia. 2013."},{"key":"key-10.7189\/jogh.12.04026-202203221410-R65","doi-asserted-by":"publisher","first-page":"CD011160","DOI":"10.1002\/14651858.CD011160.pub2","article-title":"Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.","volume":"12","author":"Zhu","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R66","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cell.2010.09.028","article-title":"Clinical application of therapies targeting VEGF.","volume":"143","author":"Yancopoulos","year":"2010","journal-title":"Cell"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R67","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ophtha.2014.11.018","article-title":"Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.","volume":"122","author":"Peden","year":"2015","journal-title":"Ophthalmology"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R68","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema.","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R69","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R70","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1016\/j.ophtha.2013.06.010","article-title":"Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study.","volume":"120","author":"Tufail","year":"2013","journal-title":"Ophthalmology"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R71","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ajo.2010.09.021","article-title":"Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment.","volume":"151","author":"Calvo-Gonzalez","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R72","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000333213","article-title":"Long-term follow-up of myopic choroidal neovascularization treated with ranibizumab.","volume":"227","author":"Franqueira","year":"2012","journal-title":"Ophthalmologica"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R73","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1136\/bjo.2009.174243","article-title":"Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study.","volume":"95","author":"Vadal\u00e0","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R74","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00417-015-3076-1","article-title":"Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes.","volume":"254","author":"Sarao","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R75","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/IAE.0b013e318261a73c","article-title":"Intravitreal pegaptanib sodium (Macugen) for treatment of myopic choroidal neovascularization: a morphologic and functional study.","volume":"33","author":"Rinaldi","year":"2013","journal-title":"Retina"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R76","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00417-006-0472-6","article-title":"Pegaptanib for myopic choroidal neovascularization in a young patient.","volume":"245","author":"Bennett","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R77","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10792-012-9532-6","article-title":"Outcome of photodynamic therapy in choroidal neovascularization due to pathologic myopia and related factors.","volume":"32","author":"Altan","year":"2012","journal-title":"Int Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R78","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/bjo.2006.106526","article-title":"Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.","volume":"91","author":"Montero","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R79","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1097\/IAE.0b013e31804b1e6f","article-title":"photodynamic therapy for Taiwanese patients with pathologic myopia: a 2-year follow-up.","volume":"27","author":"Chen","year":"2007","journal-title":"Retina"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R80","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.ajo.2007.10.032","article-title":"Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controls.","volume":"145","author":"Hayashi","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R81","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1136\/bjo.2004.041624","article-title":"Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up.","volume":"88","author":"Lam","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R82","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ajo.2010.06.046","article-title":"Long-term results of photodynamic therapy for choroidal neovascularization in Japanese patients with pathologic myopia.","volume":"151","author":"Hayashi","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R83","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ajo.2006.11.037","article-title":"Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study.","volume":"143","author":"Pece","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R84","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1097\/IAE.0b013e3181ff9546","article-title":"Photodynamic therapy in highly myopic eyes with choroidal neovascularization: 5 years of follow-up.","volume":"31","author":"Coutinho","year":"2011","journal-title":"Retina"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R85","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1097\/IAE.0b013e3182411cee","article-title":"Long-term results of photodynamic therapy for subfoveal choroidal neovascularization with pathologic myopia.","volume":"32","author":"Giansanti","year":"2012","journal-title":"Retina"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R86","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00417-005-1147-4","article-title":"Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia.","volume":"243","author":"Schnurrbusch","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R87","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0161-6420(02)01998-X","article-title":"Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial\u2013VIP report no. 3.","volume":"110","author":"Blinder","year":"2003","journal-title":"Ophthalmology"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R88","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1136\/bjophthalmol-2015-307802","article-title":"Comparison of photodynamic therapy, ranibizumab\/bevacizumab or combination in the treatment of myopic choroidal neovascularisation: a 9-year-study from a single centre.","volume":"100","author":"Rishi","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R89","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ajo.2004.06.033","article-title":"Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females.","volume":"138","author":"Postelmans","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R90","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1007\/s00417-004-0904-0","article-title":"Early neovascular bridging after photodynamic therapy of myopic choroidal neovascularization.","volume":"242","author":"Lanzetta","year":"2004","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R91","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/bjophthalmol-2014-305131","article-title":"Myopic choroidal neovascularisation: current concepts and update on clinical management.","volume":"99","author":"Wong","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"key-10.7189\/jogh.12.04026-202203221410-R92","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ajo.2006.03.003","article-title":"Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularization.","volume":"142","author":"Marticorena","year":"2006","journal-title":"Am J Ophthalmol"}],"container-title":["Journal of Global Health"],"original-title":[],"link":[{"URL":"http:\/\/jogh.org\/documents\/2022\/jogh-12-04026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T04:25:16Z","timestamp":1700367916000},"score":1,"resource":{"primary":{"URL":"http:\/\/jogh.org\/documents\/2022\/jogh-12-04026.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,26]]},"references-count":92,"URL":"https:\/\/doi.org\/10.7189\/jogh.12.04026","relation":{},"ISSN":["2047-2978","2047-2986"],"issn-type":[{"value":"2047-2978","type":"print"},{"value":"2047-2986","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,26]]},"article-number":"04026"}}